.png){kind=icon}
返回
Chagas disease
.png){kind=icon}
PRE
AI
DOI：10.1016/S0140-6736(10)60061-X.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Chagas disease is a chronic, systemic, parasitic infection caused by the protozoan Trypanosoma cruzi, and was discovered in 1909. The disease affects about 8 million people in Latin America, of whom 30-40% either have or will develop cardiomyopathy, digestive megasyndromes, or both. In the past three decades, the control and management of Chagas disease has undergone several improvements. Large-scale vector control programmes and screening of blood donors have reduced disease incidence and prevalence. Although more effective trypanocidal drugs are needed, treatment with benznidazole (or nifurtimox) is reasonably safe and effective, and is now recommended for a widened range of patients. Improved models for risk stratification are available, and certain guided treatments could halt or reverse disease progression. By contrast, some challenges remain: Chagas disease is becoming an emerging health problem in non-endemic areas because of growing population movements; early detection and treatment of asymptomatic individuals are underused; and the potential benefits of novel therapies (eg, implantable cardioverter defibrillators) need assessment in prospective randomised trials.
Keyword:
TRYPANOSOMA-CRUZI INFECTION
CURRENT EPIDEMIOLOGIC TRENDS
HEART-DISEASE
VENTRICULAR-TACHYCARDIA
NITRIC-OXIDE
FOLLOW-UP
GENETIC-VARIABILITY
CATHETER ABLATION
PREDICTING DEATH
ETIOLOGIC AGENT
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
88.5
论文数:
5.4W
被引数:
34.8W
机构
引用论文
.png){kind=icon}
Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease基于巴西医院的1220名心力衰竭门诊患者的风险分层: 查加斯病的作用
PREAI
分享收藏
查看更多内容